Follicular Lymphoma

• CLINICAL_TRIALS trial_result · 2025-09-25
  Clinical Trial Update: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma [Phase 3]

  A Phase 3 open-label randomized trial comparing Rituximab plus Lenalidomide versus Rituximab plus chemotherapy followed by Rituximab in prev…

• CLINICAL_TRIALS trial_result · 2025-09-23
  Clinical Trial Update: Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma [Phase 3]

  Phase 3 clinical trial evaluating the efficacy and safety of TQB2825 injection versus immunotherapy in recurrent or refractory follicular ly…

• CLINICAL_TRIALS trial_result · 2025-09-10
  Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]

  Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.

• CLINICAL_TRIALS trial_result · 2025-08-21
  Clinical Trial Update: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) [Phase 1]

  A Phase 1 study evaluating the safety and preliminary efficacy of INCB050465 in combination with bendamustine and obinutuzumab in relapsed o…

• CLINICAL_TRIALS trial_result · 2025-08-20
  Clinical Trial Update: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. [Phase 2]

  Phase 2 clinical trial evaluating Golcadomide (CELMoD) with rituximab, with or without nivolumab, for newly diagnosed follicular lymphoma; t…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-08-11
  Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]

  Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…

• CLINICAL_TRIALS trial_result · 2025-08-03
  Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]

  Phase 1 clinical trial update on genetically engineered CAR T cells (EGFRt/19-28z/IL-12) for relapsed or refractory CD19+ hematologic malign…

• CLINICAL_TRIALS trial_result · 2025-08-01
  Clinical Trial Update: A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) [Phase 2]

  Phase 2 trial comparing BeEAM and BEAM high-dose chemotherapy regimens before autologous stem cell transplantation in lymphoma patients; the…

• CLINICAL_TRIALS trial_result · 2025-07-10
  Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]

  A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicula…

• CLINICAL_TRIALS trial_result · 2025-07-08
  Clinical Trial Update: Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)

  This clinical trial update summarizes completed results from a surveillance study of Revlimid (lenalidomide) in relapsed or refractory folli…

• CLINICAL_TRIALS trial_result · 2025-07-04
  Clinical Trial Update: UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep [Phase 2]

  Phase 2 clinical trial evaluating non-myeloablative preparative regimens followed by umbilical cord blood transplantation for various hemato…

• CLINICAL_TRIALS trial_result · 2025-06-24
  Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…

• CLINICAL_TRIALS trial_result · 2025-06-18
  Clinical Trial Update: A Phase 1 Study of ADI-001 in B Cell Malignancies [Phase 1]

  The Phase 1 study of ADI-001 in B cell malignancies has been terminated.

• CLINICAL_TRIALS trial_result · 2025-06-17
  Clinical Trial Update: JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma [Phase 1]

  Phase 1 study of JWCAR239 for B-cell non-Hodgkin lymphoma is not yet recruiting, with indications including diffuse large B-cell lymphoma, f…

• CLINICAL_TRIALS trial_result · 2025-06-08
  Clinical Trial Update: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating the combination of obinutuzumab and lenalidomide in previously untreated Stage II-IV Grade 1-3a follicular…

• CLINICAL_TRIALS trial_result · 2025-05-16
  Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…

• CLINICAL_TRIALS trial_result · 2025-05-14
  Clinical Trial Update: Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma [Phase 3]

  A Phase 3 trial evaluating the combination of rituximab and lenalidomide in previously untreated follicular lymphoma has completed enrollmen…

• CLINICAL_TRIALS trial_result · 2025-05-14
  Clinical Trial Update: Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]

  A phase 1/2 trial evaluated a conditioning regimen incorporating venetoclax, carmustine, etoposide, cytarabine, and melphalan before stem ce…

• CLINICAL_TRIALS trial_result · 2025-05-13
  Clinical Trial Update: Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy [EARLY_Phase 1]

  A Phase 1 trial of ibrutinib in patients with follicular lymphoma who did not achieve a complete response to initial chemoimmunotherapy has …

• CLINICAL_TRIALS trial_result · 2025-05-09
  Clinical Trial Update: Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)

  A non-interventional study (URBAN) evaluated obinutuzumab for untreated follicular lymphoma and has completed with results posted.

• CLINICAL_TRIALS trial_result · 2025-04-24
  Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]

  Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …

• CLINICAL_TRIALS trial_result · 2025-04-18
  Clinical Trial Update: A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients [Phase 3]

  A Phase 3 clinical trial evaluating rituximab plus chemotherapy for follicular lymphoma in elderly patients has completed.

• CLINICAL_TRIALS trial_result · 2025-04-18
  Clinical Trial Update: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma [Phase 2]

  A Phase 2 trial evaluating pembrolizumab in combination with rituximab or obinutuzumab for relapsed or refractory follicular lymphoma or dif…

• CLINICAL_TRIALS trial_result · 2025-04-16
  Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]

  Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…

• CLINICAL_TRIALS trial_result · 2025-04-11
  Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]

  A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…